Antin Infrastructure Partners Iv Scsp (ZADOMX) News

Azitra, Inc. Announces Reverse Stock Split

Common Stock Will Begin Trading on a Split-Adjusted Basis on July 1, 2024 Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical...

Form DEF 14A - Other definitive proxy statements

Azitra, Inc. Announces Presentation at the 2024 BIO International Convention

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision...

Form PRE 14A - Other preliminary proxy statements

Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting

ATR-04 is in development for epidermal growth factor receptor inhibitor (EGFRi)-induced dermal toxicity, which affects approximately 150,000...

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting

ATR-12 has nanomolar inhibition of key protease in vitro that drives Netherton syndrome Topical application of ATR-12 to ex vivo human skin...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision...

Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting

Azitra will present two oral presentations at ASGCT (American Society of Gene and Cell Therapy) Baltimore, MD, May 7-11, 2024 related to ATR-12...

Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024

ASGCT (American Society of Gene and Cell Therapy) Baltimore, MD, May 7-11, 2024 SID (Society of Investigative Dermatology) Dallas, TX, May...

Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision...

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Azitra, Inc. Announces Closing of Public Offering

Azitra, Inc. (NYSE American: AZTR) (the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for...